Pathios Therapeutics
PrivateLast Round
Series B
Apr 18, 2024
Total Funding Raised
$39.4M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Pathios Therapeutics operates in Healthcare & Life Sciences and is based in Abingdon. Its latest recorded funding round was a Series B round in April 2024.
Pathios Therapeutics is a biotechnology company that develops small-molecule G protein-coupled receptor (GPR65) inhibitors for applications in immuno-oncology.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Pathios Therapeutics Comparables
Compare Pathios Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Cumulus Oncology | 85% | |
| Grey Wolf Therapeutics | 78% | |
| Medannex Ltd | 71% |
For institutional investors. Book with your work email.
Pathios Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Apr 18, 2024 | ||||
| Grant | Sep 27, 2023 | ||||
| Grant | Mar 8, 2021 | ||||
| Series A | Dec 18, 2019 | ||||
| Seed | Feb 6, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Pathios Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Innovate UK | Grant |
| UK government | Grant |
| Innovate UK | Grant |
| Canaan Partners | Series B, Series A |
| Brandon Capital | Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 28, 2026
Monthly visitors grew 282% MoM, reaching 1.4K.
- May 15, 2026
Monthly visitors grew 1376% MoM, reaching 1.2K.
For institutional investors. Book with your work email.
Pathios Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Pathios Therapeutics's valuation, stock price, and market status.
Is Pathios Therapeutics a public or private company?
Pathios Therapeutics is a private company.
What is the current stock price of Pathios Therapeutics?
Pathios Therapeutics is a private company, so its shares have no public market price. Caplight tracks Pathios Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Pathios Therapeutics worth (valuation)?
Valuation information for Pathios Therapeutics is not publicly available.
Can I buy Pathios Therapeutics stock?
Pathios Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Pathios Therapeutics's last funding round?
Pathios Therapeutics's most recent funding round was Series B on April 18, 2024.
Who are the main investors in Pathios Therapeutics?
Key investors in Pathios Therapeutics include Innovate UK, Canaan Partners, Brandon Capital.
Will Pathios Therapeutics IPO soon?
No public IPO plans have been announced for Pathios Therapeutics.
How can I track Pathios Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Pathios Therapeutics's shares on secondary markets.